SynGen, Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow , peripheral blood, and cell culture, announced today that it has secured additional financing from Bay City Capital, LLC, a San Francisco-based life sciences venture capital firm. Bay City Capital invested $5M in a Series A preferred stock financing of SynGen in April, 2012, and has continued to provide the company with financing in the form of convertible notes.
http://ift.tt/1s29Otq
http://ift.tt/1s29Otq
No comments:
Post a Comment